Proteomics of Severe Traumatic Brain Injury: A Feasibility Study - Full Text View

Proteomics of Severe Traumatic Brain Injury: A Feasibility Study

This study is currently recruiting participants.
Verified by University of Calgary, May 2008

Sponsors and Collaborators:	University of Calgary Canadian Intensive Care Foundation
Information provided by:	University of Calgary
ClinicalTrials.gov Identifier:	NCT00522496

Purpose

The purpose of this study is to:

Determine the temporal course of matrix metalloproteinase (MMP) expression in patients wiht severe traumatic brain injury
Determine the temporal course of the expression of MMP-related inflammatory mediators of secondary injury in patients with severe traumatic brain injury
Describe the association of physiological changes and standard microdialysis analyte measures (lactate, pyruvate, lactate/pyruvate ratio, and glucose) to MMP and neuroinflammatory marker concentrations.

Condition

Brain Injuries, Traumatic

MedlinePlus related topics:

Head and Brain Injuries

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective

Official Title:	Proteomics of Severe Traumatic Brain Injury: A Feasibility Study

Further study details as provided by University of Calgary:

Estimated Enrollment:	8
Study Start Date:	July 2007
Estimated Study Completion Date:	July 2008

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

All patients referred to Foothills Medical Centre, the regional trauma centre for Southern Alberta

Criteria

Inclusion Criteria:

Patient is 18 years of age or older
Patient has GCS less than 9
Patient requires intracranial pressure monitoring
Patient life expectancy greater than 72 hours

Exclusion Criteria:

Patient's TBI is greater than 24 hours old
Patient is less than 18 years of age
Patient does not require intracranial pressure monitoring
Patient has life expectancy less than 72 hours
Patient has GCS greater or equal to 9
Patient is currently enrolled in another study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00522496

Contacts


Contact: David A Zygun, MD	403-944-1691	dzygun@ucalgary.ca

Locations


Canada, Alberta
	Foothills Medical Centre	Recruiting
	Calgary, Alberta, Canada, T2N 2T9
	Contact: David A Zygun, MD 944-1691 dzygun@ucalgary.ca
	Principal Investigator: David A Zygun, MD
	Sub-Investigator: John Hurlbert, MD
	Sub-Investigator: Ian Parney, MD
	Sub-Investigator: Walter Hader, MD
	Sub-Investigator: Clare Gallagher, MD
	Sub-Investigator: Wee Yong, P.hD
	Sub-Investigator: Christopher Doig, MD
	Sub-Investigator: Paul Kubes, MD

Sponsors and Collaborators

University of Calgary

Canadian Intensive Care Foundation

Investigators


Principal Investigator:	Zygun A David, MD	University of Calgary

More Information

Responsible Party:	University of Calgary ( David Zygun Principal Investigator )
Study ID Numbers:	20216
First Received:	August 27, 2007
Last Updated:	May 1, 2008
ClinicalTrials.gov Identifier:	NCT00522496
Health Authority:	Canada: Ethics Review Committee

Keywords provided by University of Calgary:

Craniocerebral trauma

matrix metalloproteinase

microdialysis

Study placed in the following topic categories:

Craniocerebral Trauma

Wounds and Injuries

Disorders of Environmental Origin

Central Nervous System Diseases

Trauma, Nervous System

Brain Diseases

Brain Injuries

Additional relevant MeSH terms:

Nervous System Diseases

ClinicalTrials.gov processed this record on October 10, 2008